Rigel Pharmaceuticals

NASDAQ:RIGL   3:59:54 PM EDT
1.35
-0.14 (-9.40%)
4:00:23 PM EDT: $1.37 +0.02 (+1.48%)
Earnings Announcements

Rigel Pharmaceuticals Q2 Loss Per Share $0.08

Published: 08/02/2022 21:20 GMT
Rigel Pharmaceuticals (RIGL) - Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update.
Q2 Tavalisse Net Product Sales of $18.6 Million and Total Revenues of $29.8 Million.
Q2 Loss per Share $0.08.
Q2 Earnings per Share View $-0.12, Revenue View $23.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $22.57 Million
Adjusted EPS is expected to be -$0.14

Next Quarter Revenue Guidance is expected to be $23.06 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.